Olokizumab ELISA Kit
Olokizumab ELISA Kit is a quantitative ELISA kit for detection of Olokizumab.
Olokizumab (CDP6038), a humanized monoclonal antibody (mAb) specific for the interleukin-6 (IL-6) cytokine, is currently in development for the treatment of rheumatoid arthritis (RA). It targets the IL-6 cytokine rather than the receptor, and selectively blocks the final assembly of the signalling complex. In Phase I (healthy volunteers) and IIa (patients with RA on MTX) clinical trials, olokizumab was well tolerated after intravenous and subcutaneous delivery with a median plasma half-life of approximately 31 days, 76% bioavailability and no apparent antidrug antibody-mediated clearance. Olokizumab also markedly reduced free IL-6 levels and suppressed C-reactive protein (CRP) up to 12 weeks after single-dose subcutaneous administration in patients with RA.
Olokizumab (CDP6038), a humanized monoclonal antibody (mAb) specific for the interleukin-6 (IL-6) cytokine, is currently in development for the treatment of rheumatoid arthritis (RA). It targets the IL-6 cytokine rather than the receptor, and selectively blocks the final assembly of the signalling complex. In Phase I (healthy volunteers) and IIa (patients with RA on MTX) clinical trials, olokizumab was well tolerated after intravenous and subcutaneous delivery with a median plasma half-life of approximately 31 days, 76% bioavailability and no apparent antidrug antibody-mediated clearance. Olokizumab also markedly reduced free IL-6 levels and suppressed C-reactive protein (CRP) up to 12 weeks after single-dose subcutaneous administration in patients with RA.
Supplier | Abbexa Ltd. |
---|---|
Product # | abx395039-96T |
Pricing | 96 tests USD $942.5 |
Tested Applications | ELISA |
Test Range | 0.31 μg/ml - 5 μg/ml |
CAS Number | 1007223-17-7 |
Availability | Shipped within 5-12 working days. |
Dry Ice | No |
Note |
|